About RED 5
Red5 Pharmaceuticals, LLC is an emerging start-up company based in Cleveland, Ohio focusing on the development of innovative therapeutic agents against cancer. Our company performs the chemical synthesis and pharmaceutical testing of non-natural nucleosides as novel anti-cancer agents against hematological cancers and solid tumors. Red5 Pharmaceuticals, LLC currently leverages its patented technology in three biomedical areas described below:
1. Chemosensitizers
Developing non-natural nucleosides as adjunctive therapeutic agents that enhance the anti-cancer effects of existing chemotherapeutic agents. We have demonstrated that several of our analogs significantly increase the efficacy and potency of anti-cancer agents such as temozolomide, cisplatin, and carmustine.
2. Theranostic Agents
The development and application of non-natural nucleosides as “personalized medicines” against cancer. Primary therapeutic targets include acute lymphoblastic leukemia (ALL), Merkel cell carcinoma, and glioblastoma.
3. Diagnostic Detection of Pro-Mutagenic Replication
Using non-natural nucleotides as mechanistic probes to study the replication of damaged DNA. One goal is to detect the misreplication of specific pro-mutagenic DNA lesions in bacterial, viral, and human cells. Other applications include the use of these nucleotide anologs to PCR amplify genomic DNA containing various DNA lesions.
Board of Director
Anthony J. Berdis, Ph.D. is the Founder and Chief Scientific Officer of Red5 Pharmaceuticals, LLC. Dr. Berdis has over 15 years of professional experience in the design and testing of several distinct pharmacological agents. Over his career, he has published more than sixty (60) research articles in high impact journals. He has written several book chapters describing how bio-organic chemistry and mechanistic enzymology can be effectively used in drug discovery and target validation. He is considered an international recognized expert in the field of DNA polyemrases, DNA replication, and the development of novel nucleotide analogs to study this process.
Message from our founder.
“Cancer is a horrific disease, and one cannot help but be touched by the courage and strength of individuals who suffer from this terrible disease. At Red5 Pharmaceuticals, we are committed to develop new therapies and treatments to help patients overcome cancer. We have created the first “theranostic agent” against certain forms of pediatric leukemia, and we hope to extend this technology to treat other forms of cancers as well. These “theranostic agents” will provide patients with better therapeutic options as they possess both therapeutic and diagnostic activities.”